Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

DRUG2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV InfectionHIV Infections

Phase 1

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

RecruitingNCT02140255

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infection

Start: 2015-01-23End: 2031-12-31Target: 1120Updated: 2026-04-03

Phase 2

Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

CompletedNCT03739996

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2019-12-31End: 2024-04-29Updated: 2025-05-23

Related Papers

ART-free HIV-1 remission in children with in-utero HIV-1 after very early ART (IMPAACT P1115): a multicentre, open-label, phase 1/2 proof-of-concept study.

2025-09-25

HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study.

2023-12-0410 citations

Infants Receiving Very Early Antiretroviral Therapy Have High CD4 Counts in the First Year of Life

Clinical Infectious Diseases2022-08-295 citations

Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.

2022-05-12112 citations

Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study.

2020-11-2312 citations

The Mission is Remission

The Pediatric Infectious Disease Journal2018-10-222 citations